(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced pivotal results from the Phase 3 Krascendo 1 study, which showed superior efficacy of investigational divarasib compared with the current standard-of-care KRAS G12C inhibitors in people with previously treated